ORCID
- Michael Wilde: 0000-0003-0726-890X
Abstract
The exhaled breath represents an ideal matrix for non-invasive biomarker discovery, and exhaled metabolomics have the potential to be clinically useful in the era of precision medicine. In this concise translational review we will specifically address volatile organic compounds in the breath, with a view towards fulfilling the promise of these as actionable biomarkers, in particular for lung diseases. We review the literature paying attention to seminal work linked to key milestones in breath research; discuss potential applications for breath biomarkers across disease areas and healthcare systems, including the perspectives of industry; and outline critical aspects of study design that will need to be considered for any pivotal research going forward, if breath analysis is to provide robust validated biomarkers that meet the requirements for future clinical implementation.
DOI
10.1164/rccm.202305-0868tr
Publication Date
2024-06-18
Publication Title
Am J Respir Crit Care Med
Recommended Citation
Brinkman, P., Wilde, M., Ahmed, W., Wang, R., van der Schee, M., Abuhelal, S., Schaber, C., Cunoosamy, D., Clarke, G., Maitland-van der Zee, A., Dahlén, S., Siddiqui, S., & Fowler, S. (2024) 'Fulfilling the Promise of Breathomics: Considerations for the Discovery and Validation of Exhaled Volatile Biomarkers', Am J Respir Crit Care Med, . Available at: https://doi.org/10.1164/rccm.202305-0868tr
